The semaglutide launch date in the UK — and what's changed since

Where the decision really starts: which version of semaglutide, and when?

Most people searching for the semaglutide launch date are actually trying to answer a more practical question: is this something I can access now, and which form is actually available? The short answer is yes to both, but the options have multiplied since the original Wegovy pen launched, and knowing the timeline helps you understand what your prescriber is working with.

The story begins with MHRA approval in January 2023 for the weekly 2.4mg Wegovy injection, and you can read a full account of how that approval unfolded on the Wegovy launch page. Private availability followed a few months later; NHS access came more slowly, tied to NICE guidance published in March 2023. For most of 2023 and 2024, that single pen (starting at 0.25mg and titrated up to 2.4mg over several months) was the only licensed semaglutide option for weight management in the UK.

Then came two significant additions in quick succession. On 14 April 2026, the MHRA approved a dedicated single-dose 7.2mg pen, a step up from the original maintenance dose that trials suggested could bring average weight loss closer to 20%, narrowing the gap with tirzepatide. A month and a half later, on 11 June 2026, Wegovy tablets received MHRA approval, the first oral GLP-1 medicine licensed for weight management anywhere in Europe. The UK got there first. For anyone hesitant about injections, that matters. You can read more about how the injection and tablet compare on the Wegovy treatment page.

The NICE recommendation and the NHS timeline, what the guidance actually says

A common misconception is that MHRA approval and NHS availability are the same thing. They are not, and the gap between the two has caused a lot of frustration.

NICE published TA875 in March 2023, recommending semaglutide for adults with a BMI of 35 or above and at least one weight-related condition, but only within a specialist weight management service and for no more than two years. For most people, that means a referral, a waiting list, and a multidisciplinary programme, not a quick appointment. The ethnic-background thresholds are typically 2.5 kg/m² lower, which the NICE guidance acknowledges explicitly.

NHS England has been phasing access in gradually, with waiting lists for specialist services running long in many areas. The NICE appraisal for semaglutide outlines the eligibility criteria in detail, and it is worth reading if you are weighing up the NHS route. For tirzepatide (Mounjaro), a separate NICE appraisal, TA1026, opened up a different NHS pathway from 2025, but that is a different medicine.

Private prescribing has never required a NICE recommendation, only a clinical assessment confirming that the medicine is appropriate for you. That is why private access through a regulated UK pharmacy moved faster than NHS rollout after the January 2023 approval.

The 7.2mg pen and the Wegovy tablet, what the 2026 approvals add to the picture

The April 2026 approval of the 7.2mg single-dose pen matters because it gave prescribers a higher maintenance option for people who have plateaued at 2.4mg or who need a stronger signal to reach a clinically meaningful outcome. The pen has an auto-dosing mechanism, a covered needle, and locks after use. Crucially, it is licensed for adults with a BMI of 30 or above only, it does not extend to the lower 27–29.9 BMI band with a comorbidity. Titration still starts at 0.25mg; the 7.2mg figure is the ceiling, not the starting point.

The oral tablet, approved on 11 June 2026, climbs from 1.5mg through 4mg and 9mg to a 25mg maintenance dose. It is taken first thing in the morning on an empty stomach, with a small amount of plain water, at least 30 minutes before eating, drinking anything else, or taking other medicines. No refrigeration is needed, which makes it practical for travel and for people whose routines do not revolve around a fridge. Phase 3 trial data (OASIS 4) showed average weight loss of around 13.6% over 64 weeks versus placebo; among participants who stayed fully adherent, that figure was closer to 17%. There is no NHS appraisal for the tablet yet, it is private prescription only for now. The Wegovy weight-loss page covers the clinical evidence in more detail.

If you are curious about how the storage and dating of these medicines works in practice, the semaglutide expiry page covers what the SmPC says about shelf life and the limited room-temperature window for the injection pens.

Private access through a regulated UK pharmacy, how that route works

For people who do not meet NHS criteria, are unwilling to wait, or want the oral tablet (which has no NHS appraisal yet), private prescribing is the practical path. The legal requirement is the same regardless of route: a prescription issued by a qualified prescriber following a clinical assessment. No assessment, no prescription. That is not a bureaucratic hurdle, it is the framework that keeps these medicines safe.

At nume, consultations are reviewed the same working day by a GPhC-registered Independent Prescriber. A real clinician reads your answers; the decision is theirs, not a system's. Identity and current weight are verified, and GP records are checked where appropriate. If approved, treatment is dispatched the same day for orders placed before noon on a working day, and delivered free by DPD the next working day in plain packaging. There are no subscriptions and no automatic renewals; every repeat is reviewed again before it goes out.

You can check that any online pharmacy is legitimate using the GPhC pharmacy register, nume's registration number is 9012878. For a full picture of costs across the private market, the Wegovy pricing page covers what to expect and what the stated price should include. When you are ready to speak to a prescriber, you can start a free consultation at any point.